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Abstract
Subacute sclerosing panencephalitis (SSPE) is a fatal long-term complication of measles infection. We performed an
estimation of the total number of SSPE cases in Germany for the period 2003 to 2009 and calculated the risk of SSPE after an
acute measles infection. SSPE cases were collected from the Surveillance Unit for Rare Paediatric Diseases in Germany and
the Institute of Virology and Immunobiology at the University of Würzburg. The total number of SSPE cases was estimated
by capture-recapture analysis. For the period 2003 to 2009, 31 children with SSPE who were treated at German hospitals
were identified. The capture-recapture estimate was 39 cases (95% confidence interval: 29.2–48.0). The risk of developing
SSPE for children contracting measles infection below 5 years of age was calculated as 1:1700 to 1:3300. This risk is in the
same order of magnitude as the risk of a fatal acute measles infection.
Citation: Schönberger K, Ludwig M-S, Wildner M, Weissbrich B (2013) Epidemiology of Subacute Sclerosing Panencephalitis (SSPE) in Germany from 2003 to
2009: A Risk Estimation. PLoS ONE 8(7): e68909. doi:10.1371/journal.pone.0068909
Editor: Jean-Pierre Vartanian, Institut Pasteur, France
Received April 28, 2013; Accepted June 5, 2013; Published July 9, 2013
Copyright:  2013 Schönberger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Bavarian State Ministry of the Environment and Public Health for the ESPED data collection and by the Robert-Koch-
Institute from funds of the Federal Ministry of Health (FKZ 1369-400). Employees of the Robert-Koch-Institute provided data on measles infections in Germany,
which were reported to the Robert-Koch-Institute based on the German Infection Protection Act. These data were used for further analysis by the authors. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: weissbrich@vim.uni-wuerzburg.de
¤ Current address: Division of Epidemiology, Institute of Social Paediatrics and Adolescent Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
Introduction
Subacute sclerosing panencephalitis (SSPE) is a rare progressive,
invariably fatal long-term complication of measles infection. The
latency period between acute measles and first symptoms of SSPE
is usually 4 to 10 years but ranges from 1 month to 27 years [1].
The clinical course of SSPE varies considerably in symptoms,
duration and intensity. Typically, four disease stages are observed
beginning with changes in personality and behaviour as well as
failure in school. The second stage is characterized by massive,
repetitive, and frequent myoclonic jerks, seizures and dementia.
During the third stage, rigidity, extrapyramidal symptoms, and
progressive unresponsiveness develop. The last stage is character-
ized by coma, a vegetative state, autonomic failure or akinetic
mutism. The survival period after onset of symptoms is typically
between one to three years [2,3].
SSPE is caused by the intracerebral spread of measles virus
leading to a destruction of neurons. In all cases where brain tissue
has been examined by molecular methods, wild type measles virus
strains have been identified, never vaccine strains [1,4]. However,
the exact pathogenesis of SSPE is still unclear. There is no
evidence, that SSPE is associated with certain measles virus
genotypes or strains. Immaturity of the immune system and of the
central nervous system is thought to play a role when SSPE
develops after an early acute measles infection [5–8].
Calculation of the risk of developing SSPE after measles
infection is complex, because information on both measles and
SSPE incidences is required. The calculation is additionally
complicated by the long and variable latency period of SSPE. In
the older literature, the risk of SSPE was reported to be about
1:100000 cases of measles [9]. Later in a study from the UK, the
risk of SSPE was estimated as 1 in 90000 measles cases in children
of 5 years and older and as 1 of 5500 following measles infection in
the first year of life [10,11]. A more recent study from the USA
reported a SSPE incidence of 6.5 to 11 cases per 100000 acute
measles infections translating into a SSPE risk of 1 in 9100 to
15400 cases of measles [4]. A distinction of age groups was not
made in this study.
The SSPE incidence may differ geographically and may change
over time. Because there are only few current studies addressing
the risk of SSPE, further studies are indicated in order to enlarge
the epidemiological knowledge of this disastrous disease. For
Germany, there is no notification or central documentation of
SSPE cases. Therefore, information on the absolute number of
SSPE cases and on the SSPE incidence in Germany is lacking.
The aim of this study was to combine information on SSPE cases
in Germany from different sources for the period 2003 to 2009, to
estimate the total number of SSPE cases in children younger than
16 years of age in Germany and to calculate the risk of developing
SSPE after an acute measles infection.
Methods
Ethics Statement
This study was approved by the ethics committee of the medical
faculty at the University of Würzburg. Data collection and analysis
within the Surveillance Unit for Rare Paediatric Diseases in
Germany (ESPED) was approved by the ethics committee of the
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Bavarian Medical association. Informed consent by the patients or
their guardians was not required by both ethics committees,
because the data were analyzed anonymously.
Data Sources of SSPE Cases
Information on SSPE cases for the period from 2003 to 2009
was obtained from two sources. The first dataset consisted of SSPE
cases diagnosed at the Institute of Virology and Immunobiology at
the Julius-Maximilian University Würzburg (ViroWue). Because of
SSPE research interests, this institute has been involved in the
diagnosis of SSPE for about 30 years. It is the appointed
consultant laboratory for viral diseases of the central nervous
system in Germany. From 1987 to 2010, samples of about 150
SSPE cases have been received from German hospitals for
primary or confirmatory SSPE diagnosis.
The second data source was based on ESPED, a voluntary
reporting system, which actively collects anonymous monthly
reports from all German paediatric hospitals and departments on
selected rare paediatric diseases. ESPED comprises a reminder
and dunning system in order to collect missing reports. The return
rate of monthly reports has been $95% since 1999 [12]. The
spectrum of rare diseases, which are surveyed, has been changed
on a regular basis. From 2003 to 2009, ESPED collected data
about hospitalized children younger than 16 years of age with
measles and its complications including SSPE. The Bavarian
Health and Food Safety Authority (LGL) initiated and financed
the survey. It was responsible for compilation of reported cases and
for obtaining further information thereon. For that purpose, the
LGL contacted the reporting paediatricians, who were asked to
return an anonymous structured questionnaire about the case with
questions on age, symptoms, diagnosis, complications, treatment
and vaccination status. Additionally, an anonymized medical
discharge letter was requested. The return rate of the question-
naires by the responsible physicians was 93.8% for this study.
Data Sources of Measles Cases
Numbers of acute measles infections in Germany were obtained
from two different official data sources. According to the German
Infection Protection Act (IfSG), acute measles has been a notifiable
disease since 2001. Data are collected by the health authorities of
the federal German states and are reported to the Robert Koch-
Institut (RKI), a central institution of the Federal Ministry of
Health, which is responsible for disease control and prevention.
Notification according to IfSG includes information about the
hospitalization status of patients with acute measles. Notification
data are publicly accessible (http://www3.rki.de). For the purpose
of this study, numbers of notified acute measles infections for the
period of 2001 to 2009 grouped by year, age, and hospitalization
status were directly obtained from the RKI. These data allowed
calculating a ratio between all measles cases and hospitalized
measles cases (see below).
Before 2001, acute measles infection had not been a notifiable
disease. Therefore, other indicators were sought in order to
estimate the yearly numbers of measles infections. Since 1993,
cumulated diagnosis data of hospitalized patients in Germany
have been collected by the Federal Statistical Office as part of the
German hospital statistics. These data have included information
on hospitalized measles cases. All measles related hospitalizations
covered by codes 055 of the International Classification of
Diseases (ICD)-9 and codes B05 of ICD-10 were selected. For
the year 1993, only incomplete data were available. For the years
1994 to 1999, hospitalization data on patients with measles, sorted
by ICD and age groups, were directly obtained from the Federal
Statistical Office. For the years 2000 to 2009, data on hospitalized
measles cases were obtained from a publicly accessible online-
database (http://www.gbe-bund.de). Data from the German
hospital statistics were only available in clustered age groups
(1994–1999: age groups 0 to ,5 and $5 to ,15 years of age;
2000–2009: age groups 0 to ,5, $5 to ,10, and $10 to ,15
years of age).
Case Definition, Data Merging and Validation
Laboratory diagnosis of SSPE at ViroWue was based on
established criteria including oligoclonal bands, intrathecal mea-
sles virus-specific IgG synthesis and excessively high absolutes titres
of measles virus IgG in both serum and CSF. In each case, the
laboratory diagnosis was complemented by clinical findings that
were consistent with SSPE. Reports of SSPE cases by the ESPED
surveillance system were checked for plausibility by contacting the
reporting paediatrician. Fulfilment of diagnostic criteria for SSPE
was confirmed based on discharge reports. Discharge reports were
not available for two cases captured only by ESPED (number 19
and 30 in table 1).
Because the ESPED data were limited to children younger than
16 years of age during the period 2003 to 2009, we restricted our
study of SSPE cases to this period and age group. Cases from both
SSPE data sources were matched and merged based on
information contained in both data sets (month and year of birth,
second letter of pre- and surname, time and city of hospitalization).
Matching of cases was performed independently by two investi-
gators of the study (KS and BW) yielding identical results. For all
uniquely identified cases, information on acute measles infection
was used for further analysis if available. Children with SSPE from
abroad who were only hospitalized in Germany for diagnostic
purposes were excluded from the analysis. However, children
residing in Germany were included independent of their ethnic
background.
Calculation of Total Number of SSPE Cases by Capture-
recapture Method
To estimate the total number of SSPE cases in Germany during
the period 2003 to 2009, we used the capture-recapture method.
Both SSPE data sources collected the data simultaneously and
independently in accordance with the requirements for this
method. The capture-recapture estimator and its confidence
interval were calculated according to LaPorte et al. [13].
Calculation of the SSPE Risk after Known Measles
Infection
For the age group below 5 years of age, the SSPE cases in the
numerator were taken from the years 2003 to 2009 (study period).
The corresponding measles cases were taken from the years 1994
to 2001 as ‘‘at-risk’’-population (years of known measles
infections).
Results
SSPE Case Identification and Capture-recapture
Calculation
After merging the SSPE cases from ViroWue and ESPED, 38
unique SSPE cases who were diagnosed at ViroWue and/or
reported to ESPED at some point during 2003 to 2009 were
identified. Of these, four cases were excluded because they had no
residence in Germany and another three cases because they were
older than 16 years of age at the time of SSPE diagnosis. The
remaining 31 cases fulfilled the case definition and were included
in further analysis (table 1). Of these 31 cases, 11 (31%) were
Risk Estimation of SSPE, Germany
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captured by both data sources, 13 (42%) were captured exclusively
by ViroWue, and seven (23%) exclusively by the ESPED
surveillance system. Based on information available to ViroWue
and ESPED, all children had their primary SSPE diagnoses at the
time they were captured, except for cases number 9 and 10
(table 1), who were both captured by ESPED in 2004 but were
primarily diagnosed with SSPE in 2002, when ESPED was not yet
collecting cases with measles complications. By capture-recapture
analysis, the estimated total number of SSPE cases in Germany
during the period 2003 to 2009 was 39 (95% confidence interval
[CI]: 29.2–48.0; table 2) in children younger than 16 years of age.
SSPE Case Descriptions
Twenty-one of the 31 children with SSPE were male and 8 were
female (male-to-female ratio 2.6:1). The gender of two patients was
unknown. Information about nationality was available for 23 of
the 31 cases; 11 children were German, 6 Turkish, 2 Kosovarian,
and 4 had other non-German nationalities (table 1). The median
and mean age at SSPE diagnosis was 9 years (range 1 to 13 years).
Of the 21 cases with a known history of measles infection, the
median and mean age at time of measles infection was 1 year and
all children were younger than 3 years of age. The median latency
period between measles infection and SSPE diagnosis was 8 years




































1 ViroWue, ESPEDa 2003 male Kosovan 1996 2003 7 n. i. n. i. n. i. n. i. 2 5/7
2 ViroWue, ESPED 2003 male Turkish 1997 2003 6 1998 1 born in
Germanyb
5 n. i. n. i.
3 ViroWue, ESPED 2003 male Turkish 1995 2003 8 n. i. n. i. born in
Germanyb
n. i. 2 1/4
4 ViroWue 2003 male Iraqi 1994 2003 9 1996 2 n. i. 7 2 3/7
5 ViroWue 2003 female n. i. 1995 2003 8 n. i. n. i. n. i. n. i. n. i. n. i.
6 ESPED 2003 male Croatian 1996 2003 7 1997 1 n. i. 6 n. i. n. i.
7 ESPED 2004 male German 1998 2004 6 1999 1 Germanyb 5 1 2
8 ViroWue 2004 n. i. n. i. 1996 2004 8 n. i. n. i. n. i. n. i. 2 3/6
9 ViroWue a, ESPED 2004 male German 1997 2002 5 1998 1 Germanyb 4 n. i. n. i.
10 ViroWue a, ESPED 2004 female n. i. 1992 2002 10 1994 2 n. i. 8 n. i. n. i.
11 ViroWue, ESPED 2005 male German 1995 2005 10 1996 1 Germanyb 9 2 7/8
12 ViroWue, ESPED 2005 male Angolan 1992 2005 13 1993 1 n. i. 12 1 12
13 ViroWue, ESPED 2005 female German 1995 2005 10 1996 1 Germanyb 9 1 1
14 ViroWue 2005 female Turkish 1995 2005 10 1996 1 n. i. 10 n. i. n. i.
15 ViroWue 2005 female German 1995 2005 10 1995 0 Germanyb 10 2 n. i.
16 ViroWue 2005 n. i. n. i. 1996 2005 9 n. i. n. i. n. i. n. i. n. i. n. i.
17 ViroWue 2005 male n. i. 1997 2005 8 n. i. n. i. n. i. n. i. n. i. n. i.
18 ESPED 2005 male German 1994 2005 11 1995 1 Germanyb 10 n. i. n. i.
19 ESPED 2005 male Kosovan 1994 2005 11 n. i. n. i. n. i. n. i. 1 n. i.
20 ESPED 2005 male Turkish 1995 2005 10 1996 1 n. i. 9 2 1/4
21 ViroWue, ESPED 2005 male Turkish 2004 2005 1 n. i. n. i. n. i. n. i. 1 1
22 ViroWue 2006 male n. i. 2001 2006 5 2001 1 Germanyc 4 2 1/n. i.
23 ViroWue 2006 male n. i. 1993 2006 13 n. i. n. i. n. i. n. i. n. i. n. i.
24 ViroWue 2006 male German 1997 2006 9 1998 1 Germanyb 8 n. i. n. i.
25 ViroWue 2006 male Tamil 1998 2006 8 1999 ,1 Germanyc 7 n. i. n. i.
26 ViroWue, ESPED 2007 female German/Romanian 1998 2007 9 1999 1 Germanyb 8 n. i. n. i.
27 ESPED 2007 female Turkish 1999 2007 8 2000 1 n. i. 7 3 n. i.
28 ViroWue, ESPED 2008 female German 2005 2008 3 2006 1 Germanyb 2 1 2
29 ViroWue 2008 male German 1996 2008 12 1997 1 Germanyb 11 1 1
30 ESPED 2008 male German 1998 2008 10 1999 1 Germanyb 9 2 7/10
31 ViroWue 2009 male n. i. 1997 2009 12 n. i. n. i. n. i. n. i. n. i. n. i.
abbreviations: n. i. – no information, ESPED - Surveillance Unit for Rare Paediatric Diseases in Germany, ViroWue - Institute of Virology and Immunobiology at the
University of Würzburg,
areported to ESPED in 2004, samples tested at ViroWue in 2002.
bcountry of infection assumed to be Germany because of German nationality and/or birth in Germany.
ccountry of infection Germany based on anamnestic information.
doi:10.1371/journal.pone.0068909.t001
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(mean 7.6 years; range 2 to 12) (table 1). A yearly distribution of
the acute measles infections of these 21 children is shown in
figure 1. Except for one case of measles infection in 2006, all other
infections occurred during the period of 1993 to 2001. Informa-
tion about the vaccination status and/or the age at the time of
measles vaccination was available for 17 children. Insofar as it was
known, vaccination took place later than infection with the
measles virus.
Calculation of the Risk of SSPE after Acute Measles
Infections
For the children with SSPE and known history of measles in the
period 1993 to 2001, calculation of the risk to develop SSPE was
attempted. To this end, knowledge of the total number of measles
cases as denominator is necessary. As mentioned above, acute
measles has been a notifiable disease in Germany only since 2001
as regulated by IfSG. Since 1993, however, the Federal Statistical
Office has collected data on the number of hospitalized measles
cases as part of the German hospital statistics. Because these data










All children with SSPE of this study 24a 18 11a 31 38.6 (29.2–48.0)
Children with SSPE, who possibly contracted measles infection in
Germany 1994–2001b
13 12 6 19 25.0 (16.3–33.7)
Children with SSPE, who probably contracted measles infection in
Germany 1994–2001b, c
10 8 5 13 15.5 (10.7–20.3)
abbreviations: ESPED - Surveillance Unit for Rare Paediatric Diseases in Germany, ViroWue - Institute of Virology and Immunobiology at the University of Würzburg, CI –
confidence interval.
aCases 9 and 10 of table 1 (captured by ESPED in 2004, samples tested by ViroWue in 2002) were included.
bChildren with missing information on year of measles infection were excluded.
cGerman children and/or children born in Germany. Children with missing information on nationality and/or country of birth or infection were excluded.
doi:10.1371/journal.pone.0068909.t002
Figure 1. Year of primary diagnosis of subacute sclerosing panencephalitis (SSPE) and year of measles infection. Data are shown for
SSPE cases identified in Germany from 2003 to 2009. Two SSPE cases reported to the German Surveillance Unit for Rare Paediatric Diseases (ESPED) in
2004 were primarily diagnosed in 2002. Numbers of measles cases are extrapolated based on German hospital statistics for the period 1994–2000. For
the period 2001–2009, measles cases reported by the German Infection Protection Act (IfSG) are displayed.
doi:10.1371/journal.pone.0068909.g001
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were incomplete for the starting year 1993 of hospital statistics, this
year was excluded from further calculations.
Based on the assumption, that the ratio between hospitalized
cases and all measles cases was nearly constant during the period
of 1994 to 2009, we determined this ratio on the basis of all IfSG
notifications from 2001 to 2009 (‘‘pooled IfSG hospitalization
rate’’). Using this ratio, we extrapolated the number of all measles
cases for the period from 1994 to 2001 from German hospital
statistics data. This extrapolation was performed for the age group
of children below 5 years of age, because all children with SSPE
and known history of measles infection were below 5 years of age
at the time of acute measles infection. The pooled IfSG
hospitalization rate was 0.092 for this age group (table 3). Using
this rate, we extrapolated the number of measles cases per year
from the numbers of hospitalized cases reported by the German
hospital statistics. In total, approximately 43000 measles cases
were assumed to have occurred in Germany from 1994 to 2001 in
children younger than 5 years of age (table 3).
The validity of this approach was assessed for the period 2001 to
2009, during which both data sources (notification by IfSG and
German hospital statistics) were available (table 3). The total
number of IfSG measles notifications was 4956. The total number
of measles cases extrapolated from German hospital statistics using
the pooled IfSG hospitalization rate was 7641. This approach was
further validated in the age group$5 and ,15 years (table 4).
Overall, 7525 children with measles infection were reported by
IfSG and 344 of these were hospitalized, yielding a pooled IfSG
hospitalization rate of 0.046. Using this rate, the number of
measles infections extrapolated from German hospital statistics
was 11112. Thus, measles case extrapolations from German
hospital statistics and the number of IfSG measles notifications
were in fairly good agreement in both age groups with German
hospital statistics derived numbers being about 1.5fold higher than
IfSG notifications.
Using the number of measles cases extrapolated from German
hospital statistics for the period 1994 to 2001 as denominator, the
risk of developing SSPE was calculated for children with measles
infection below 5 years of age. With respect to the numerator, i. e.
the number of SSPE cases, we made various assumptions (table 5).
When all captured children with SSPE were considered, for whom
the year of measles infection was known and the country of
infection was possibly Germany (n = 19), the incidence of SSPE
was 1 of 2240 measles infections. Using the capture-recapture
estimate as denominator (n = 25), the incidence was 1 of 1702
measles infections. Given the fact, that precise information on the
country of measles infection was not available for all SSPE cases,
we performed similar calculations with restriction to the children
of German nationality and/or children born or anamnestically
infected in Germany (n = 13). The ensuing SSPE incidence was 1
of 3273 measles cases, which increased to 1 of 2660 measles cases
when the capture-recapture estimate of SSPE cases (n = 16) was
used.
Discussion
We estimated the risk of developing SSPE after acute measles
infection below 5 years of age to be in the range of 1 in 1700 to 1
Table 3. Extrapolation of the total number of measles cases from 1994 to 2009 in Germany for children ,5 years of age a.
Year
Reported measles









,5 years (GHS data)
Measles cases in children ,5
years extrapolated from GHS
data using the IfSG
hospitalization rate
1994 no data available no data available 383 4163
1995 no data available no data available 691 7511
1996 no data available no data available 1628 17696
1997 no data available no data available 284 3087
1998 no data available no data available 276 3000
1999 no data available no data available 213 2315
2000 no data available no data available 175 1902
2001 1839 161 0.088 265 2880
2002 1542 94 0.061 153 1663
2003 285 13 0.046 34 370
2004 60 9 0.150 22 239
2005 207 20 0.097 33 359
2006 536 86 0.160 103 1120
2007 126 12 0.095 29 315
2008 196 22 0.112 28 304
2009 165 37 0.224 36 391
Total 1994–2000 3650 39674
Total 2001–2009 4956 454 0.092 703 7641
Total 1994–2001b 3915 42554
abbreviations: IfSG - German Infection Protection Act, GHS – German hospital statistics.
aNumbers in columns 2–5 are reported data; numbers in column 6 (in italics) represent extrapolations from GHS data using the pooled hospitalization rate derived form
IfSG data for the years 2001 to 2009 (454/4956 = 0.092).
bTime period used for SSPE risk estimation.
doi:10.1371/journal.pone.0068909.t003
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in 3300 cases of measles infection. Because SSPE is not a notifiable
disease in Germany nor were acute measles infections notifiable
before 2001, several assumptions were made for the risk
calculations. Concerning the number of SSPE cases, we focused
on the years 2003 to 2009 because two independent data sources
were available for this period. One data source was ESPED, a
voluntary reporting system, which has actively collected monthly
reports from all German paediatric hospitals and departments on a
predefined spectrum of rare paediatric diseases. Measles and its
complications – including SSPE – had been part of the ESPED
survey from 2003 to 2009. The second data source was provided
by ViroWue, which is the consultant laboratory for viral diseases
of the central nervous system in Germany and receives samples of
SSPE patients for confirmatory diagnosis on a voluntary basis.
Because ViroWue is only one of many laboratories in Germany
offering diagnostic tests for SSPE, it is unclear in how far these
cases are representative for the whole of Germany. Availability of
these two data sources for the years 2003 to 2009 provided the
unique opportunity of a capture-recapture-analysis of SSPE cases
in Germany for this period. Both data sources combined, 31 SSPE
cases had been observed. By capture-recapture estimation, the
total number of SSPE cases for the period 2003 to 2009 was 39
(95% CI: 29.2–48.0). Thus, this analysis provided evidence that
both data sources had collected about 84% but at least more than
half of all SSPE cases from German hospitals in children younger
than 16 years of age. Consequently, the SSPE cases captured by













cases in children $5
and
,15 years (GHS data)
Measles cases in children $5
and ,15 years extrapolated
from GHS data using the IfSG
hospitalization rate
1994 no data available no data available 247 5403
1995 no data available no data available 490 10719
1996 no data available no data available 1288 28175
1997 no data available no data available 234 5119
1998 no data available no data available 191 4178
1999 no data available no data available 147 3216
2000 no data available no data available 158 3456
2001 2692 109 0.040 177 3872
2002 2271 93 0.041 141 3084
2003 369 12 0.033 17 372
2004 25 2 0.080 11 241
2005 386 16 0.041 21 459
2006 961 70 0.073 86 1881
2007 240 9 0.038 16 350
2008 427 18 0.042 18 394
2009 154 15 0.097 21 459
Total 1994–2000 2755 60266
Total 2001–2009 7525 344 0.046 508 11112
abbreviations: IfSG - German Infection Protection Act, GHS – German hospital statistics.
aNumbers in columns 2–5 are reported data; numbers in column 6 (in italics) represent extrapolations from GHS data using the pooled hospitalization rate derived form
IfSG data for the years 2001 to 2009 (344/7525 = 0.046).
doi:10.1371/journal.pone.0068909.t004
Table 5. Estimation of the risk of subacute sclerosing panencephalitis (SSPE) in Germany after acute measles during the period
1994 to 2001a.
Assumption on measles













possibly in Germany captured cases 19 ,5 years 42554 1 of 2240 44.6
capture-recapture estimation 25 ,5 years 42554 1 of 1702 58.8
probably in Germany captured cases 13 ,5 years 42554 1 of 3273 30.6
capture-recapture estimation 16 ,5 years 42554 1 of 2660 37.6
aThe estimation was based on children with SSPE diagnosis during 2003 to 2009, who had a history of acute measles infection during 1994 to 2001.
bDetails are explained in Table 2.
doi:10.1371/journal.pone.0068909.t005
Risk Estimation of SSPE, Germany
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ESPED and ViroWue were assumed to be representative for the
German situation and could therefore be used for calculations of
the risk of SSPE after measles infection.
Capture-recapture estimations are useful to compensate for the
insufficiency of surveillance systems. They are based on five central
assumptions: (1) cases have to be clearly identifiable as cases, (2)
double notifications of identified cases have to be clearly
detectable, (3) cases have to be descended from a closed
population, (4) homogeneity in capture of cases, and (5)
independence of both data sets [14]. These five prerequisites were
considered to be reasonably fulfilled, because (1) diagnostic criteria
for SSPE are clearly defined, (2) unequivocal case matching was
possible based on the available information from both data
sources, (3) analysis was restricted to German hospitals and
patients living in Germany, (4) severity of SSPE symptoms with
progression suggests that disease diagnosis will be attempted in all
cases, and (5) independence of data sets was assumed because both
collection systems were fundamentally different with ViroWue
being part of the diagnostic and confirmatory process and ESPED
being a reporting system for already diagnosed cases. However,
positive dependence of both capture systems is not unlikely,
because diagnosis of SSPE is a prerequisite for the disease to be
reported by ESPED as demonstrated, e.g., by cases 9 and 10.
Because positive dependence will result in underestimation of the
true population size, the effect on SSPE risk calculation will
equally be underestimation. Nevertheless, even if the assumption
of independence was violated, capture-recapture analysis would
still be useful by providing a lower limit of the SSPE cases [15].
The available information about the SSPE cases was heteroge-
neous. Yet, the overall demographic characteristics of our cohort
with a male preponderance and median age of 9 years were in
good agreement with data from the literature [review in 1,2,16].
Information about a history of acute measles infection was
available for 21 children with SSPE. These children provided
the basis of calculations of the SSPE risk. Their median age at the
time of measles infection (1 year; range 0–2 years) as well as the
latency period until diagnosis of SSPE (median 8 years; range 2–12
years) were again in accordance with the results from other studies
[review in 1,2,16]. Precise information on the country where acute
measles infection took place was not available for most of the
children with SSPE. This aspect is discussed below.
Concerning the denominator of the SSPE risk calculations, i.e.
the number of cases with acute measles infections, we were faced
with the problem that most of the measles infections in the cohort
of our SSPE patients took place before the start of mandatory
measles notification in Germany in 2001. Therefore, extrapolation
of the total number of measles cases in the 1990s was attempted on
the basis of hospitalized acute measles cases recorded through the
German hospital statistics system starting in 1993. Comparison of
data derived from IfSG and the German hospital statistics for the
period 2001 to 2009 provided evidence that this approach was
valid.
Yearly hospitalization rates derived from IfSG data of the years
2001 to 2009 varied by a factor of about 5 for the age group,5
years and by a factor of about 3 for the age group$5 and ,15
years (column 4 in tables 3 and 4). Therefore, we used the pooled
hospitalization rate, which is mainly influenced by the years with
large numbers of measles cases and is more robust against
variation seen in years with small numbers of measles cases. This
has two additional effects. Firstly, the data from the German
hospital statistics suggest that during the IfSG reporting period, the
measles epidemiology of the years 2001 and 2002 is most similar to
the period 1994 to 2000 when IfSG reporting was not yet
instituted. Because 2001 and 2002 were the years with the largest
numbers of measles cases reported by IfSG, they mainly influence
the pooled hospitalization rate. This indicates, that the pooled
IfSG hospitalization rate is representative for the period 1994 to
2000. Secondly, the hospitalization rates for the years 2001 and
2002 and as a result the pooled hospitalization rate are
comparatively low (column 4 in Tables 3 and 4). When
extrapolating the number of measles cases from the German
hospital statistics, the effect of using a low hospitalisation rate is a
tendency to overestimate measles cases.
Based on the combined cohorts of SSPE patients and the
estimated yearly numbers of acute measles cases, the risk of
developing SSPE was calculated. For the children with known
history of acute measles, almost all infections took place in the
period of 1994 to 2001 and all children were younger than 3 years
of age at the time of acute measles. Several of these children had a
migration background and information on where acute measles
infection took place was not available for all cases. The
conservatively calculated SSPE risk taking into account only
children infected probably in Germany was 1 in 3300 cases of
acute measles in children below 5 years of age. The risk increased
to 1 in 2240 when children possibly infected with measles virus in
Germany were added.
Calculation of the SSPE risk is limited by uncertainties with
respect to the number of acute measles cases and the number of
SSPE cases. Underestimation of the number of acute measles cases
may lead to overestimation of the risk of SSPE. In how far this
may have occurred is unclear. In a study of the 2006 measles
outbreak in Germany, IfSG notification data were compared with
billing data received by statutory health insurance carriers from
physicians [17]. Based on this comparison, under-reporting by
IfSG in the age group of ,5 years of age was estimated to be
about fourfold while there appeared to be considerably less
underreporting in all other age groups. This striking difference
between age groups remained unexplained. Furthermore, it is
unclear whether the billing data were more reliable than IfSG
notification data, because in the former there may be a tendency
to report suspected measles cases as confirmed measles cases. At
any rate, the use of measles case numbers extrapolated from
German hospital statistics in our study appeared to decrease the
effect of under-reporting, which may be inherent to IfSG data,
because numbers derived from German hospital statistics were
about 1.5fold higher than IfSG notifications.
Underestimation of the number of SSPE cases may lead to
underestimation of the actual risk of SSPE. Several factors suggest,
that underestimation of SSPE cases is a relevant issue. Firstly,
some of the patients without known history of measles infection
may have had acute measles in the period from 1994 to 2001.
Secondly, further SSPE cases resulting from measles infections in
the period 1994 to 2001 may have had their primary diagnosis
before or after the observation period 2003 to 2009 of this study.
Thirdly, only SSPE cases in children younger than 16 years of age
were captured for this study because of restrictions of the data
collection system (ESPED inclusion criteria). And finally, capture-
recapture analysis suggested that the true number of SSPE
diagnoses from 2003 to 2009 was probably higher than observed.
In addition, the age-specific risk of SSPE is likely to be higher for
children below 3 years of age, because all children with known
history of measles were 2 years or younger at the time. However,
extrapolation of the total number of measles cases was only
possible in 5-year-age groups due to limitations imposed by the
German hospital statistics with respect to age-specific data. Within
the IfSG notifications, the proportion of children below 3 years of
age among the age group of children below 5 years of age is 59.6%
for all cases of measles and 81.5% for hospitalized cases of measles.
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From these data, it can be estimated that the SSPE risk for
children below 3 years of age was about 1.7fold higher than the
risk for the larger group of children below 5 years of age.
Unfortunately, the risk of SSPE for children above 5 years of
age at the time of measles infection could not be calculated for two
reasons. On the one hand, data about measles virus infections for
the period 1994 to 2001 were available only as clustered numbers
for the age group 6 to 15 years of age. On the other hand, SSPE
cases were collected only for children younger than 16 years of age
by ESPED. Because of the long latency period of SSPE it is
evident, that SSPE cases resulting from measles infections in
children at the age of 6 to 15 years would, at best, be only partially
detected by ESPED.
Nevertheless, the age distribution at the time of acute measles in
our study suggests that the risk of developing SSPE is particularly
high after measles infection in the first two to three years of life and
decreases thereafter. This is in line with previous observations and
highlights the importance of vaccination against measles at the
earliest age recommended by national guidelines [1,10,11,18].
Measles vaccination provides protection against SSPE as long as
wild-type measles infection does not occur before vaccination [1].
However, due to the presence of maternal antibodies, the
recommended age for the first measles vaccination is usually
around the end of the first year of life. Prevention of SSPE by
protection from wild-type measles infection in children below 1
year of age can only be achieved by herd immunity ensuing from
sufficient vaccination coverage population wide. This is an
important aspect in the context of the elimination of measles,
because the risk of developing SSPE may be in the order of 1:1000
measles cases or even higher after measles infection in the first year
of life.
In conclusion, this study provides data on the SSPE epidemi-
ology in Germany for the period 2003 to 2009. Our data suggest
that the risk of developing SSPE after acute measles infection
below 5 years of age is in the range of 1:1700 to 1:3300. This
considerable risk for a disastrous yet preventable disease should be
incorporated in every risk-benefit-education of measles vaccination
and may constitute an important component of communication
about the rationale for measles elimination.
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